What is the dosage and treatment protocol for Augmentin (amoxicillin-clavulanate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Augmentin (Amoxicillin-Clavulanate) Dosing and Treatment Protocol

For adults with mild-to-moderate infections, use 500 mg/125 mg three times daily or 875 mg/125 mg twice daily; for respiratory infections specifically, the 875/125 mg twice-daily formulation is preferred. 1

Standard Adult Dosing Regimens

Oral Formulations

Mild-to-Moderate Infections:

  • 500 mg amoxicillin/125 mg clavulanate three times daily provides adequate coverage for most community-acquired infections 1
  • This dosing is appropriate for uncomplicated skin infections, mild respiratory infections, and urinary tract infections 1

Respiratory Tract Infections (Preferred):

  • 875 mg/125 mg twice daily is specifically recommended for acute bacterial rhinosinusitis, community-acquired pneumonia, and acute exacerbations of chronic bronchitis 1
  • Duration for uncomplicated acute bacterial rhinosinusitis is 5-7 days 1
  • For pneumonia, continue treatment for 5-7 days if afebrile for 48 hours and clinically stable 1

Skin and Soft Tissue Infections:

  • 875 mg/125 mg twice daily for standard infections 1
  • 500 mg/125 mg twice daily for animal or human bites 1, 2
  • Duration: 5-7 days after clinical improvement 2

Intravenous Formulations

Serious Infections:

  • 1.2 g IV every 8 hours for complicated intra-abdominal infections, severe respiratory infections, and severe skin/soft tissue infections 1, 2
  • For moderate-to-severe community-acquired pneumonia requiring hospitalization, this three-times-daily dosing provides optimal pharmacodynamic coverage 2
  • Duration for intra-abdominal infections: 4-7 days with adequate source control 1

Alternative IV Dosing:

  • For intra-abdominal infections in non-critically ill patients: 2 g/0.2 g every 8 hours 2

Pediatric Dosing

Urinary Tract Infections (Ages 2-24 Months):

  • 20-40 mg/kg per day (amoxicillin component) divided into 3 doses 3
  • Total treatment duration: 7-14 days 3
  • Avoid nitrofurantoin in febrile infants, as it does not achieve adequate parenchymal concentrations for pyelonephritis 3

Acute Bacterial Rhinosinusitis:

  • 90 mg/6.4 mg/kg per day (high-dose formulation) 2

Recurrent/Persistent Acute Otitis Media:

  • 90 mg/6.4 mg/kg per day in two divided doses (Augmentin ES-600 formulation) for children with risk factors for beta-lactamase-producing strains or penicillin-resistant S. pneumoniae 4

Streptococcal Carrier State:

  • 40 mg/kg/day (amoxicillin component) divided into three doses for 10 days (maximum 2000 mg amoxicillin per day) 1, 2

Special Clinical Scenarios

Lyme Disease with Cellulitis:

  • 500 mg three times daily for 14 days when covering both Lyme disease and bacterial cellulitis 1

Recurrent Streptococcal Pharyngitis:

  • 500 mg twice daily for 10 days in adults with multiple recurrent episodes 1
  • For chronic carriers: 500 mg (amoxicillin component) twice daily for 10 days 1

Critical Dosing Considerations and Pitfalls

Formulation Substitution Error:

  • Never substitute two 250 mg tablets for one 500 mg tablet, as this results in excessive clavulanate dosing and increased gastrointestinal side effects 1

Treatment Duration:

  • Complete the full course of therapy to prevent treatment failure and resistance development 1
  • For streptococcal infections, minimum 10 days of therapy is required to prevent acute rheumatic fever 1, 2

Drug Interactions:

  • Not recommended with probenecid 2
  • May increase prothrombin time with oral anticoagulants; monitor INR closely 2

Local Resistance Patterns:

  • Know local susceptibility patterns for E. coli and other coliforms before prescribing, particularly for urinary tract infections 3
  • Geographic variability in resistance to trimethoprim-sulfamethoxazole and cephalexin affects empiric therapy choices 3

Transition from IV to Oral Therapy

Criteria for Transition:

  • Clinical improvement within 24-48 hours of IV therapy 3
  • Ability to retain orally administered fluids and medications 3
  • Patient no longer appears "toxic" 3
  • Continue oral therapy to complete the 7-14 day total course 3

References

Guideline

Amoxiclav Dosing Guidelines for Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Augmentin Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.